Back to top

Oruka Therapeutics Rises as Investors Focus on Pipeline Data Setup

Oruka Therapeutics (ORKA) is up 7.7% today. Here is some analysis on what might have caused this price movement.

Analysis: A single fresh company announcement does not appear to explain today’s move, so the catalyst is somewhat unclear. This could be because investors are refocusing on Oruka’s strong psoriasis data, its cash position after a large spring financing, and the next round of efficacy and durability readouts expected in the second half of 2026.

Details:

  • Oruka’s April psoriasis update showed ORKA-001 reached a 63.5% PASI 100 rate at Week 16, giving the stock a clinical-data foundation that traders may still be rewarding.
  • The company has said longer-term EVERLAST-A data, including Week 28 efficacy and follow-up durability information, is expected in the second half of 2026, keeping another visible catalyst on the calendar.
  • Management said in May that post-offering capital is expected to fund the company through an anticipated biologics license application for ORKA-001, easing some balance-sheet pressure after an upsized $700 million public offering.
  • A recent analyst target increase also highlighted expectations for upcoming second-half data, which may be helping sentiment as the market looks ahead rather than reacting to new same-day news.

    • Sources:

    Oruka Therapeutics Investor Relations, SEC, TipRanks

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $ORKA Insider Trading Activity

    ORKA Insider Trades

    $ORKA insiders have traded $ORKA stock on the open market 57 times in the past 6 months. Of those trades, 0 have been purchases and 57 have been sales.

    Here’s a breakdown of recent trading of $ORKA stock by insiders over the last 6 months:

    • FUNDS MANAGEMENT LLC FAIRMOUNT sold 3,553,410 shares for an estimated $300,014,406
    • CARL DAMBKOWSKI has made 0 purchases and 5 sales selling 140,000 shares for an estimated $8,645,748.
    • JOANA GONCALVES (Chief Medical Officer) has made 0 purchases and 20 sales selling 43,588 shares for an estimated $2,589,427.
    • ARJUN AGARWAL (Senior Vice President, Finance) has made 0 purchases and 15 sales selling 32,125 shares for an estimated $2,285,803.
    • LAURA LEE SANDLER (Chief Operating Officer) has made 0 purchases and 13 sales selling 16,200 shares for an estimated $1,025,878.
    • LAWRENCE OTTO KLEIN (Chief Executive Officer) has made 0 purchases and 2 sales selling 3,458 shares for an estimated $191,901.
    • PAUL T QUINLAN (General Counsel) sold 733 shares for an estimated $51,082

    To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    $ORKA Hedge Fund Activity

    We have seen 112 institutional investors add shares of $ORKA stock to their portfolio, and 39 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $ORKA Price Targets

    Multiple analysts have issued price targets for $ORKA recently. We have seen 8 analysts offer price targets for $ORKA in the last 6 months, with a median target of $122.5.

    Here are some recent targets:

    • Michael Yee from UBS set a target price of $130.0 on 07/01/2026
    • Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $120.0 on 06/23/2026
    • Julian Harrison from BTIG set a target price of $151.0 on 05/14/2026
    • Etzer Darout from Barclays set a target price of $160.0 on 04/28/2026
    • Martin Fan from Wedbush set a target price of $85.0 on 04/15/2026
    • Yatin Suneja from Guggenheim set a target price of $125.0 on 04/13/2026
    • David Risinger from Leerink Partners set a target price of $86.0 on 03/16/2026

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Read full article here »

    In-Depth Zacks Research for the Tickers Above

    Normally $25 each - click below to receive one report FREE:

    Oruka Therapeutics, Inc. (ORKA)